Study outlines potential new probiotic strain with anti-inflammatory action

By Stephen Daniells

- Last updated on GMT

© sefa ozel / Getty Images
© sefa ozel / Getty Images

Related tags Probiotic Anti-inflammatory IBD Gut health

A potential probiotic isolated from the rumen of grazing lamb may protect against damage of colon cells and reduce markers of inflammation, says a new study.

French scientists also report that Ligilactobacillus salivarius​ CNCM I-4866 does not contain the genes for antibiotic resistance and mainly produces L-lactate with very little D-lactate. Animal data indicates that L-lactate may alleviate intestinal inflammation, while accumulation of D-lactate can lead to detrimental effects in people with short bowel syndrome.

“Our study has shown that a new strain, L. salivarius​ CNCM I-4866, displays strong anti-inflammatory capacities in vitro​ and in vivo​,” scientists from INRAE at the Université Paris-Saclay wrote in the journal Frontiers in Microbiology.

“Even if further research could be useful to better understand the mechanisms involved or to test this strain on moderate inflammation, CNCM I-4866 is confirmed to be a promising probiotic candidate to alleviate inflammation at the preclinical level on a DNBS model, mimicking IBD and, more specifically, Crohn’s disease.”

Study details

Led by Célia Carbonne and Rebeca Martin, the researchers assessed the safety and efficacy of L. salivarius​ CNCM I-4866, which was as isolated by French company Sorbial. The strain’s potential anti-inflammatory properties were investigated using a mouse model of acute inflammation colitis induced by a chemcical called dinitrobenzene sulfonic acid (DNBS).

Results of the DNMS experiment indicated that the CNCM I-4866 group of mice displayed less intestinal permeability (which is known to increase with inflammation) and to decrease select biomarkers of inflammation.

Additional in vitro​ experiments supported these initial findings, with data showing promotion of an anti-inflammatory effect by decreasing, for example, the production of IL-8, a pro-inflammatory marker.

Moreover, the strain was found to inhibit several intestinal pathogens, such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium​ and S. enteritidis.

The researchers also investigated the strain’s technical and safety profile, noting that no  antibiotic gene resistance was found, and the strain was “highly resistant to 0.3% of bile salts”.

“Taken together, these results indicate that L. salivarius​ CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile,” concluded the researchers.

Source: Frontiers in Microbiology
Volume 14 – 2023, doi: 10.3389/fmicb.2023.1270974
Ligilactobacillus salivarius​ CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro​ and in vivo​”
Authors: C. Carbonne, et al.


Related news

Related products

show more

New postbiotic for gut & skin health benefits

New postbiotic for gut & skin health benefits

Content provided by Kerry ProActive Health | 14-May-2024 | Product Presentation

Plenibiotic™ (Lactobacillus casei subsp. casei 327) is a rice-derived postbiotic providing a holistic approach to digestive and skin health. It offers...

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-May-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

Related suppliers

Follow us


View more